UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For
the month of October
Commission
File Number:
(Translation of Registrant’s Name into English)
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
This report on Form 6-K is incorporated by reference into the registrant’s registration statement on Form F-3 (File No. 333-271901).
Genenta Science S.p.A. Reports Financial Results for the Six Months Ended June 30, 2024
Genenta Science S.p.A. (“Genenta”) is furnishing this report on Form 6-K to provide its unaudited consolidated financial statements as of June 30, 2024, and for the six months ended June 30, 2024, and June 30, 2023, and to provide its Management’s Discussion and Analysis of Financial Condition and Results of Operations with respect to such financial statements.
The unaudited consolidated financial statements as of June 30, 2024, and for the six months ended June 30, 2024, and June 30, 2023, are attached to this Form 6-K as Exhibit 99.1. Management’s Discussion and Analysis of Financial Condition and Results of Operations is attached to this Form 6-K as Exhibit 99.2.
As described in more detail in Note 15, Subsequent events to the financial statements attached as Exhibit 99.1 hereto, on September 19, 2024, Genenta entered into an amendment to the Master Services Agreement with AGC Biologics S.p.A. (“AGC”) to extend the term of the Master Services Agreement. Additionally, on October 14, 2024, Genenta entered into an Agreement for the Conduct of Clinical Trials on Medical Products with San Raffaele Hospital (“OSR”) to conduct an open-label 1/2 clinical trial in Renal Cell Cancer. The descriptions of the amendment to the Master Services Agreement and the Agreement for the Conduct of Clinical Trials on Medical Products contained in this Form 6-K and in Exhibits 99.1and 99.2 hereto do not purport to be complete and are qualified in their entirety by reference to the complete text thereof, copies of which are filed as exhibits 10.1 and 10.2, respectively, to this Form 6-K.
EXHIBIT INDEX
| Exhibit | Title | |
| 10.1 | Amendment to the AGC Master Service Agreement dated September 19, 2024. | |
| 10.2 | Agreement for the Conduct of Clinical Trials on Medicinal Products with OSR dated October 14, 2024. | |
| 99.1 | Unaudited Consolidated Financial Statements as of June 30, 2024, and for the six months ended June 30, 2024, and June 30, 2023. | |
| 99.2 | Management’s Discussion and Analysis of Financial Condition and Results of Operations. | |
| 101 | The following materials from Genenta’s Report on Form 6-K for the six months ended June 30, 2023, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations and Comprehensive Loss, (iii) the Consolidated Statements of Changes in Shareholders’ Equity, (iv) the Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENENTA SCIENCE S.P.A. | ||
| Date: October 29, 2024 | By: | /s/ Pierluigi Paracchi |
| Pierluigi Paracchi, Chief Executive Officer | ||